---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019852"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:07:04.204002+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Celcuity Q1 net loss $21.6M; Phase 3 VIKTORIA-1 on track for H2 2024 data

## Summary
- Net loss $21.6M ($0.64/sh) vs $11.9M ($0.55/sh) in Q1 2023; cash $177.7M expected runway into H1 2026.
- Phase 3 VIKTORIA-1 on track: topline PIK3CA wild-type data H2 2024; mutant sub-group H1 2025.
- First patient dosed in Phase 1b/2 trial of gedatolisib + darolutamide for mCRPC; prelim data expected H1 2025.
- Appointed Eldon Mayer as CCO in Feb 2024 to prepare for potential gedatolisib launch.
- R&D expenses $20.7M (up $9.4M YoY) driven by VIKTORIA-1 and new trial initiation.

## SEC filing metadata
- accession: 0001493152-24-019852
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000149315224019852/0001493152-24-019852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000149315224019852/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019852
- JSON: https://secwatch.observer/filing/0001493152-24-019852.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019852.txt

## Key facts
- Earnings Releases
  Celcuity Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $21.6 million, or $0.64 loss per share, EPS $0.64 loss per share.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss for the first quarter of 2024 was $21.6 million, or $0.64 loss per share
  - EPS: $0.64 loss per share
  - Result: reported results
  source text: Celcuity Inc. (the “Company”) issued a press release regarding the Company’s financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1603454/000149315224019852/0001493152-24-019852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.